Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients

Transplantation

Volumn 97, Issue 5, 2014, Pages 569-575

  Jamal, Alainna J ^a   Husain, Shahid ^a,b   Li, Yanhong ^a   Famure, Olusegun ^a,b   Kim, S Joseph ^a,b,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cytomegalovirus; Kidney function; Kidney transplantation

Indexed keywords

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; INFECTION RISK; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANSPLANTATION;

EID: 84896318998     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000438197.38413.f2     Document Type: Article

References (37)

1. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12: 848
2. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the 'silo' hypothesis. Curr Opin Infect Dis 2007; 20: 399
3. Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307
4. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103:106
5. Cainelli F, Vento S. Infections and solid organ transplant rejection: A cause-And-effect relationship? Lancet Infect Dis 2004; 2: 539
6. Humar A, Gillingham KJ, Payne WD, et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 1879
7. Kern F, Ode-Hakim S, Nugel H, et al. Peripheral T cell activation in long-Term renal transplant patients: Concordant upregulation of adhesion molecules and cytokine gene transcription. J Am Soc Nephrol 1996; 11: 2476
8. De Keyzer K, Van Laecke S, Peeters P, et al. Human cytomegalovirus and kidney transplantation: A clinician's update. Am J Kidney Dis 2011; 58: 118
9. Doyle AM, Warburton KM, Goral S, et al. 24-Week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106
10. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-Term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975
11. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840
12. Humar A, Snydman B, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9: S78
13. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solidorgan transplantation. Transplantation 2013; 96: 333
14. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 6
15. Murray BM, Subramanian S. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Transpl Infect Dis 2004; 6: 3
16. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days of valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228
17. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovirresistant cytomegalovirus disease among recipients of solid organ transplants. Lancet 2000; 356: 645
18. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62: 7
19. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134
20. Kijpittayarit S, Deziel P, Eid AJ, et al. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation 2006; 81: 137
21. Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis 2011; 13: 244
22. Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+/Rj kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011; 11: 1936
23. Luan FL, Samaniego M, Kommareddi M, et al. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transpl Infect Dis 2010; 12: 473
24. Helantera I, Kyllonen L, Lautenschlager I, et al. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 2010; 10: 2026
25. Freeman RB, Paya C, Pescovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis cessation in highrisk solid-organ transplant recipients. Transplantation 2004; 78: 1765
26. Rubin RH. Infections disease complications of renal transplantation. Kidney Int 1993; 44: 221
27. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 1993; 3: 1541
28. Chonchol M. Neutrophil dysfunction and infection risk in end-stage renal disease. Semin Dial 2006; 19: 291
29. Girndt M, Sester M, Sester U, et al. Molecular aspects of T-And B-cell function in uremia. Kidney Int Suppl 2001; 78: S206
30. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 2001; 15: 813
31. Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005; 46: 997
32. Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: Results of the HEMO Study. J Am Soc Nephrol 2003; 14: 1863
33. Allon M, Radeva M, Bailey J, et al. The spectrum of infection-related morbidity in hospitalized haemodialysis patients. Nephrol Dial Transplant 2005; 20: 1180
34. Dalrymple LS, Johansen KL, Chertow GM, et al. Infection-related hospitalizations in older patients with ESRD. Am J Kidney Dis 2010; 56: 522
35. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262
36. Sis B, Mengel M, Haas M, et al. Banff '09 Meeting Report: Antibody mediated graft deterioration and implementation of Banff Working Groups. Am J Transplant 2010; 10: 464
37. Vasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834